Emerging drugs for restless legs syndrome (Q36219646)

12 August 2017

1 reference

title

Emerging drugs for restless legs syndrome (English)

1 reference

12 August 2017

main subject

restless legs syndrome

0 references

author name string

Stephany Fulda

series ordinal

1 reference

12 August 2017

Thomas C Wetter

series ordinal

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Emerging Drugs

12 August 2017

published in

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

537-552

1 reference

Epidemiology of restless legs symptoms in adults

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Functional neuroimaging studies in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Why do restless legs occur at rest?--pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Restless legs syndrome: a review of clinical and pathophysiologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Studies of penetrance and anticipation in five autosomal-dominant restless legs syndrome pedigrees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Restless legs syndrome in 218 patients: associated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Secondary periodic limb movement disorder and restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

An algorithm for the management of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

A randomized controlled study of pergolide in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Long-term effects of pergolide in the treatment of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Treatment of restless leg syndrome with pergolide--an open clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Effective cabergoline treatment in idiopathic restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Fibrosis associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Piribedil for restless legs syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Apomorphine in idiopathic restless legs syndrome: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Treatment of periodic leg movement disorder and restless leg syndrome with talipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Long-term follow-up on restless legs syndrome patients treated with opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Clonazepam and vibration in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Chronic hypnotic use: deadly risks, doubtful benefit. REVIEW ARTICLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Pilot trial of lamotrigine in the restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Restless legs syndrome: confirmation of linkage to chromosome 12q, genetic heterogeneity, and evidence of complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Iron, brain and restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

MRI measurement of brain iron in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

The treatment of restless legs syndrome with intravenous iron dextran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Ropinirole for restless legs syndrome: a placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Ropinirole for restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Restless legs syndrome improved by pramipexole: a double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Encouraging initial response of restless legs syndrome to pramipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Effect of pramipexole in treatment of resistant restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Low-dose pramipexole in the management of restless legs syndrome. An open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Pramipexole in Restless Legs syndrome. Evaluation by suggested immobilization test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Entacapone in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Treatment of idiopathic restless legs syndrome (RLS) with gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Restless legs syndrome: an historical note

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Enhanced external counter pulsation (EECP) as a novel treatment for restless legs syndrome (RLS): a preliminary test of the vascular neurologic hypothesis for RLS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.10.3.537

10.1517/14728214.10.3.537

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference